Key Points• Pharmacokinetic (PK) data, which shows how long...

Key Points
• Pharmacokinetic (PK) data, which shows how long paxalisib remains in the human
body, strongly supports 60mg once daily dosing, confirming planned administration
schedule for commercial launch.
• Analysis of food effect shows no significant difference between taking paxalisib with
food versus on an empty stomach, allowing for a less restrictive administration
schedule in commercial use.
• Study remains ongoing, with a number of patients still in follow-up. Final data is now
expected in 2H CY2021.

Kazia CEO, Dr James Garner, commented, “this is extremely useful and encouraging data, as
we begin to compile regulatory documentation for paxalisib and give shape to its potential
commercial approval. These results give us great confidence that we are administering the
drug at the right dose, at the right frequency, and under the correct conditions. Moreover,
the data helps to confirm the approach that we have taken in the GBM AGILE pivotal study.”